Provided by Tiger Trade Technology Pte. Ltd.

Xeris Pharmaceuticals Inc

6.51
-0.2100-3.12%
Post-market: 6.510.00000.00%19:17 EST
Volume:2.04M
Turnover:13.33M
Market Cap:1.08B
PE:-62.36
High:6.80
Open:6.75
Low:6.47
Close:6.72
52wk High:10.08
52wk Low:3.14
Shares:165.92M
Float Shares:159.00M
Volume Ratio:1.05
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1044
EPS(LYR):-0.3736
ROE:-617.16%
ROA:2.88%
PB:-1254.55
PE(LYR):-17.42

Loading ...

Xeris Biopharma Officer Beth Hecht Reports Disposal of Common Shares

Reuters
·
Dec 03

Xeris Biopharma Holdings Inc - Unit Receives Uspto Notice of Allowance for XP-8121 Patent

THOMSON REUTERS
·
Dec 01

Xeris Biopharma Receives Notice of Allowance from USPTO for XP-8121 Patent Application

Reuters
·
Dec 01

Xeris Biopharma Q3 Net Income USD 621 Thousand

Reuters
·
Nov 20

Xeris Biopharma Holdings Inc. Director and Officer John Patrick Shannon Jr. Reports Disposal of Common Shares

Reuters
·
Nov 18

Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade

Simply Wall St.
·
Nov 17

Xeris Biopharma Holdings Inc. Officer Beth Hecht Reports Disposal of Common Shares

Reuters
·
Nov 14

Xeris Biopharma Holdings Inc : Leerink Partners Raises Target Price to $11 From $9

THOMSON REUTERS
·
Nov 13

Craig-Hallum Remains a Buy on Xeris Pharmaceuticals (XERS)

TIPRANKS
·
Nov 08

Xeris Biopharma price target raised to $8 from $6 at Piper Sandler

TIPRANKS
·
Nov 07

Xeris Biopharma Down Over 21%, On Pace for Largest Percent Decrease Since June 2020 -- Data Talk

Dow Jones
·
Nov 07

Stock Track | Xeris Pharmaceuticals Plunges 16.41% Despite First-Ever Quarterly Profit as Revenue Guidance Disappoints

Stock Track
·
Nov 06

Stock Track | Xeris Pharmaceuticals Plummets 16.41% After Q3 Revenue Miss and Lowered 2025 Guidance

Stock Track
·
Nov 06

Xeris Biopharma Q3 2025 Earnings Call Summary and Q&A Highlights: Record Revenue and Strategic Expansion

Earnings Call
·
Nov 06

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript

Motley Fool Transcribing
·
Nov 06

Earnings Flash (XERS) Xeris Biopharma Posts Q3 EPS $0, vs. FactSet Est of $0

MT Newswires Live
·
Nov 06

Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market Following Q3 Earnings and Revenue Guidance Update

Stock Track
·
Nov 06

Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market on Q3 Revenue Miss and Updated Guidance

Stock Track
·
Nov 06

Xeris Biopharma Holdings Q3 Sales $74.380M Beat $74.180M Estimate

Benzinga
·
Nov 06

Xeris Biopharma Reports 40% Year-Over-Year Revenue Growth in Q3 2025

Reuters
·
Nov 06